Leerink Swann Weighs in on Neovasc Inc’s Q2 2019 Earnings (NVCN)
Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) – Equities research analysts at Leerink Swann issued their Q2 2019 earnings per share estimates for shares of Neovasc in a report issued on Thursday, November 15th. Leerink Swann analyst D. Antalffy expects that the medical equipment provider will earn $0.01 per share for the quarter. Leerink Swann also issued estimates for Neovasc’s Q3 2019 earnings at $0.01 EPS.
Several other research firms have also issued reports on NVCN. ValuEngine upgraded Neovasc from a “hold” rating to a “buy” rating in a research report on Saturday, September 22nd. Zacks Investment Research lowered Neovasc from a “hold” rating to a “sell” rating in a research report on Tuesday, August 14th.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Gagnon Advisors LLC grew its position in shares of Neovasc by 2,416.2% in the 2nd quarter. Gagnon Advisors LLC now owns 46,032,686 shares of the medical equipment provider’s stock worth $1,970,000 after buying an additional 44,203,204 shares during the last quarter. Gagnon Securities LLC grew its position in shares of Neovasc by 350.7% in the 2nd quarter. Gagnon Securities LLC now owns 19,120,325 shares of the medical equipment provider’s stock worth $818,000 after buying an additional 14,878,428 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Neovasc by 837.5% in the 2nd quarter. Renaissance Technologies LLC now owns 53,754,832 shares of the medical equipment provider’s stock worth $2,300,000 after buying an additional 48,020,900 shares during the last quarter. Finally, Capital Research Global Investors bought a new stake in shares of Neovasc in the 3rd quarter worth approximately $1,917,000.
Neovasc Company Profile
Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.
Featured Story: Asset Allocation and Your Retirement
Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.